--- title: "Weekly Recap | TMO.US +6.83%, setting a 52-week high" type: "News" locale: "en" url: "https://longbridge.com/en/news/299515333.md" description: "Thermo Fisher (TMO) gained 6.83% this week to close at $651.45, outperforming the S&P 500, which slipped 0.08%, by roughly 6.91 percentage points. The move was a step-like rally rather than a straight line. Monday opened at $614.94 and dipped to $605.65, then Tuesday jumped 4.52% to $641.39 on heavier volume. Wednesday and Thursday added more upside, with Thursday touching an intraday high of $663.57 before Friday eased back to $651.45. Weekly amplitude came in at 9." datetime: "2026-09-19T06:57:20.000Z" locales: - [zh-CN](https://longbridge.com/zh-CN/news/299515333.md) - [en](https://longbridge.com/en/news/299515333.md) - [zh-HK](https://longbridge.com/zh-HK/news/299515333.md) generator: "portal-rs" --- # Weekly Recap | TMO.US +6.83%, setting a 52-week high ## The Week Thermo Fisher (TMO) gained 6.83% this week to close at $651.45, outperforming the S&P 500, which slipped 0.08%, by roughly 6.91 percentage points. The move was a step-like rally rather than a straight line. Monday opened at $614.94 and dipped to $605.65, then Tuesday jumped 4.52% to $641.39 on heavier volume. Wednesday and Thursday added more upside, with Thursday touching an intraday high of $663.57 before Friday eased back to $651.45. Weekly amplitude came in at 9.42%, and average daily volume of about 3.19 million shares ran roughly 72% above the 60-day median, pointing to unusually active trading. ## Key Events Several items this week centred on management’s upbeat tone for 2026. On 15 September, reports highlighted strong Q2 growth, AI-driven demand and reshoring trends as supports for a multi-year outlook, and the stock rose 3.44%. On 17 September, the company said it expects stronger demand and called 2026 an ‘outstanding year’. The next day, during regular trading, the stock reached a 52-week high, with management signalling a positive biopharma growth outlook. Friday brought a pullback and underperformance. The storyline was consistent: company-level comments focused on biopharma demand and AI-related opportunities, and the share price moved higher in tandem, setting a 52-week high midweek. ## Analyst Ratings Among 31 analysts covering the stock, 20 rate it buy, 4 rate it outperform, 4 rate it hold, 1 rates it underperform, 2 have no opinion, and none rate it sell. The consensus rating is buy, with a consensus target of $645.15, about 0.97% below the latest price of $651.45. That means the stock now trades slightly above the average analyst target. Targets range from $520 to $750, a wide spread that reflects disagreement about the longer-term upside. Within the life science tools and services industry, TMO ranks first among 54 companies. ## The Week Ahead The macro calendar is relatively quiet next week. The main US releases fall on 24 September: initial jobless claims, the current account balance and new home sales. After management’s stronger-demand comments this week, the focus will be on whether that optimism gets backed up by more supply-chain data, along with any fresh signs on biopharma orders and AI-related demand. Another angle is price action near the highs: shares set a 52-week high on Thursday and pulled back on Friday, so how the stock behaves around record levels will be worth tracking. ## In Short The tension this week is between a fresh 52-week high and a consensus target that now sits below the spot price. Analysts still collectively rate the stock a buy and place it first in its industry, but the consensus target of $645.15 is slightly under the latest close, meaning the average expected upside has narrowed after the run-up. On the latest trading day, large orders were net buyers by about $30.61 million, with small and medium orders also net inflows, so short-term participation had not faded. The question going forward is whether management’s strong demand outlook translates into verifiable orders and revenue, and how well the stock holds near record levels. *This article is generated by LongbridgeAI from market data, for information only and not investment advice.* ### Related Stocks - [TMO.US](https://longbridge.com/en/quote/TMO.US.md) ## Related News & Research - [Thermo Fisher Scientific Non-GAAP EPS of $6.68 beats by $0.28, revenue of $12.14B beats by $190M](https://longbridge.com/en/news/302544681.md) - [TD Cowen maintains Buy rating on Thermo Fisher Scientific, $810 price target](https://longbridge.com/en/news/302741090.md) - [Thermo Fisher Q3 revenue, adj profit beat estimates after new product launches](https://longbridge.com/en/news/302543566.md) - [Thermo Fisher Scientific Q3 2026 Earnings Call Transcript](https://longbridge.com/en/news/302560965.md) - [Thermo Fisher Stock Hits Record High: What's Happening?](https://longbridge.com/en/news/300056069.md) --- > **Disclaimer: This article is for reference only and does not constitute any investment advice.**